Insulin and insulin delivery systems leader Novo Nordisk India Pvt. Ltd is all set to launch Novo Mix 30 by the end of July and introduce NovoPen 4. While Novo Mix 30 is a pre-mixed dual action insulin, NovoPen 4 is an advanced version of its previous device NovoPen 3.
The Novo Pen is available in the global market for more than 20 years. However, its sales are comparatively less in India, which has a large diabetic population. NovoPen was introduced as an easy to use device compared to the traditional insulin injections. In the last two decades, NovoPen has undergone several enhancements with versions like NovoPen 3, Novolet & Flexpen. While NovoPen 3 and Flexpen are ready to use disposable delivery devices, NovoPen 3 is a permanent delivery device. All these pens are used with Novofine 31 G needle, which is made with thin wall technology for smooth and virtually painless Insulin injection.
“Those patients who have been put on the pen, prefer to administer insulin with the help of devices and the main reason behind is clear and accurate dose scale, elegant design and discreet action,” stated Sanjiv Shishoo, managing director, Novo Nordisk India Pvt. Ltd.
In India, there are 32 million diabetics and barely 5% of use the pen devices, compared to Europe where usage is over 90 per cent. Almost three and a half million people worldwide use a NovoPen system for their daily insulin injections; this number however covers up for huge regional differences. India has attained the dubious distinction of being termed the 'Diabetes Capital' of the world, accounting for more than 3 crore people having the disease and at least 1 in 3 needing insulin for a better life. As on date only 12-14% are treated, he informed.